Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study

Table 4 Refractory odds ratios for characteristics of baseline and early therapy in high cumulative dosage subgroup

Characteristics of baseline and early therapy (High)^a	Combined multivariate analyses
Characteristics of baseline and early therapy (High)^a	Refractory, % (n/N)	OR (95% CI)	P value
Age, year
≥ 36	52.4 (22/42)	Reference
< 36	65.3 (47/72)	1.0 (0.4–2.5)	0.980
GO, n (%)
Yes	80.6 (25/31)	4.1 (1.3–13.4)	0.019
No	53.0 (44/83)	Reference
Initial goiter size (cm³)
≥ 11.5	63.2 (67/106)	3.4 (0.5–23.0)	0.216
< 11.5	25.0 (2/8)	Reference
Initial fT3 (pmol/L)
≥ 31.3	61.6 (45/73)	0.8 (0.2–2.8)	0.713
< 31.3	58.5 (24/41)	Reference
Initial fT4 (pmol/L)
≥ 67.7	60.2 (50/83)	1.7 (0.4–6.8)	0.457
< 67.7	61.3 (19/31)	Reference
Initial TRAb (IU/L)
≥ 17.5	68.5 (37/54)	1.2 (0.4–3.6)	0.783
< 17.5	53.3 (32/60)	Reference
TPOAb (3 m)^b (IU/mL)
≥ 174.3	76.9 (40/52)	3.5 (1.4–8.8)	0.006
< 174.3	46.8 (29/62)	Reference
TRAb (3 m accumulation)^c (day* IU/L)
≥ 937.0	70.3 (45/64)	2.0 (0.7–6.2)	0.209
< 937.0	48.0 (24/50)	Reference

GO, Graves’ orbitopathy, fT3 free triiodothyronine, fT4 free thyroxine, TPOAb thyroid peroxidase autoantibody, TRAb thyroid stimulating hormone receptor autoantibody, OR odds ratio, CI confidence interval, m month
^a3-month high cumulative MMI dosage group (≥ 1730 mg, average ≥ 20 mg/day, N = 114)
^bAbsolute serum TPOAb level at 3 months of MMI therapy
^cThe area under the fitted curve of 0–3 months serum TRAb level after the start of MMI therapy (the abscissa is days, the ordinate is the TRAb level)

ISSN: 1479-5876